1589.3000 2.60 (0.16%)
NSE Sep 29, 2025 15:31 PM
Volume: 4.2M
 

1589.30
0.16%
Prabhudas Lilladhar
Better product mix and lower overheads drive core EBITDAM. We upgrade our recommendation on SUNP to Buy as we stand convinced on growth prospect of its specialty portfolio, in spite of sectoral headwinds in key markets. While we maintain our assigned PE at 24x on FY23E earnings to derive TP of Rs922 (earlier 773), slower growth of overhead costs in...
Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.
More from Sun Pharmaceutical Industries Ltd.
Recommended